Literature DB >> 2557669

The gastric H+,K+-ATPase: the site of action of omeprazole.

G Sachs1, B Wallmark.   

Abstract

The mammalian parietal cell is dedicated to the secretion of HCl in response to various stimuli and second messengers. Oxidative metabolism in the cell increases about 10-fold in order to supply ATP to the gastric proton pump, the H+,K+-ATPase. This pump appears to be present only in the parietal cell. This membrane-embedded enzyme uses the scalar energy of ATP hydrolysis to carry out the vectorial transport of H+ in one direction in exchange for K+ in the other direction. In the cytoplasmic vesicle, K+ does not permeate the membrane, whereas in the secretory canaliculus, there is a Cl- channel and a KCl cotransport pathway which allow K+ and Cl- to exit from the cell. The K+ is then recycled back into the cell by the ATPase, and H+ secretion occurs into the canalicular space. Although there are other proton pumps, only the gastric H+,K+-ATPase has this exchange mechanism and only the gastric H+,K+-ATPase is able to generate a pH of less than 4. Thus the gastric proton pump has a unique structure and mechanism, and produces a unique luminal pH. This enzyme is therefore an appropriate target for rational drug design.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2557669

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  11 in total

1.  Chronic omeprazole treatment increases duodenal susceptibility to ethanol injury in rats.

Authors:  R A Erickson; S Bezabah; G Jonas; E Lifrak; A S Tarnawski
Journal:  Dig Dis Sci       Date:  1991-07       Impact factor: 3.199

2.  Acid-suppressive effects of various regimens of omeprazole in Helicobacter pylori-negative CYP2C19 homozygous extensive metabolizers: which regimen has the strongest effect?

Authors:  Tomohiko Shimatani; Tomoko Kuroiwa; Mutsuko Moriwaki; Jing Xu; Susumu Tazuma; Masaki Inoue
Journal:  Dig Dis Sci       Date:  2007-04-05       Impact factor: 3.199

3.  Omeprazole produces parietal cell hypertrophy and hyperplasia in humans.

Authors:  D K Driman; C Wright; G Tougas; R H Riddell
Journal:  Dig Dis Sci       Date:  1996-10       Impact factor: 3.199

Review 4.  Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.

Authors:  J A Goldstein
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

Review 5.  Clinical pharmacology of omeprazole.

Authors:  C W Howden
Journal:  Clin Pharmacokinet       Date:  1991-01       Impact factor: 6.447

6.  Comparative study of the control of basal acid output from rodent isolated stomachs.

Authors:  N J Welsh; N P Shankley; J W Black
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

7.  Efficacy of a paste formulation of omeprazole for the treatment of naturally occurring gastric ulcers in training standardbred racehorses in Canada.

Authors:  Michèle Y Doucet; André A Vrins; Rachel Dionne; Roberto Alva; Glenn Ericsson
Journal:  Can Vet J       Date:  2003-07       Impact factor: 1.008

8.  Omeprazole inhibits natural killer cell functions.

Authors:  Huseyin Alkim; Selahattin Unal; Hamza Okur; Turgut Imir
Journal:  Dig Dis Sci       Date:  2007-06-28       Impact factor: 3.199

Review 9.  Progress with proton pump inhibition.

Authors:  N J Bell; R H Hunt
Journal:  Yale J Biol Med       Date:  1992 Nov-Dec

10.  Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans.

Authors:  M Katashima; K Yamamoto; Y Tokuma; T Hata; Y Sawada; T Iga
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jan-Mar       Impact factor: 2.569

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.